EGFR and adenocarcinoma: Results of the IPASS phase 3 trial, conducted in a population of 1217 patients with clinical characteristics predictive of EGFR mutations (namely East Asian nonsmokers with adenocarcinoma), provide additional support for the activity of gefitinib in this setting 24,25.